trending Market Intelligence /marketintelligence/en/news-insights/trending/_9nIMd1sx9clfIoiI5mQnA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Teva's generic HIV medicine enters US market; drug price hikes shrink

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Teva's generic HIV medicine enters US market; drug price hikes shrink

Top news

* Teva Pharmaceutical Industries Ltd. launched the first generic version of Bristol-Myers Squibb Co.'s HIV-1 drug Reyataz in the U.S. The treatment, also known as atazanavir, had annual sales of about $402 million in the U.S.

* Average annual price hikes for 20 top-selling brand-name prescription drugs in the U.S. have declined for at least 4 consecutive years, STAT reported, citing data from Truven Health Analytics Inc.

M&A and capital markets

* Alliance Pharma plc completed its acquisition of the worldwide rights to TyraTech Inc.'s head lice treatment Vamousse. TyraTech's shareholders approved the deal on Dec. 27.

Operational activity

* The Court of Appeal for the district of Munich in Germany dismissed Novartis AG's appeal in a patent infringement lawsuit against Luye Pharma Group Ltd.'s Rivastigmine 1 day patch, a treatment for Alzheimer's disease.

* UAE-based private equity business TVM Capital Healthcare Partners started a $250 million healthcare fund that would invest in areas such as cancer and pharmaceuticals in markets including the Gulf, Turkey, India, Egypt and Singapore, Reuters reported, citing a senior executive of the firm.

* Evan Greebel, a former lawyer for Retrophin Inc., was found guilty of helping former Retrophin CEO Martin Shkreli misappropriate $11 million from the company to pay back investors after risky trades by the executive, Bloomberg News reported. Shkreli was found guilty of fraud by a U.S. court in August.

Other features

* Republicans are under pressure to steady the country's healthcare system after President Donald Trump signed the tax cut bill, which removed a requirement for every American to have health insurance or pay a fine, known as the individual mandate, under the Affordable Care Act, the Financial Times writes.

The day ahead

Early morning futures indicators pointed to a higher opening for the U.S. market.

In Asia, the Hang Seng was up 0.90% to 29,863.71. The Nikkei 225 fell 0.56% to 22,783.98.

In Europe as of midday, the FTSE 100 was up 0.14% to 7,631.42, while the Euronext 100 was down 0.04% to 1,041.59.

The Daily Dose is updated as of 6:30 a.m. ET. Some external links may require a subscription.